跳到主要內容區塊

醫學生物技術暨檢驗學系 (醫技系)

國立陽明大學

周德盈

Curriculum Vitae

Name

Teh-Ying Chou, MD, PhD, MBA

Title

Chair, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, TAIWAN

Address

No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City, 11217, TAIWAN

Email

tychou@vghtpe.gov.tw

Telephone

886-2-2875-7080, 7022

 

 

EDUCATION

2013-2016

 

1990-1995

EMBA

 

Ph.D.

International Business

Biochemistry, Cellular and Molecular Biology Training Program

National Taiwan University College of Management, Taiwan

Johns Hopkins University School of Medicine

(Thesis Advisors: Gerald W. Hart and Chi V. Dang)

 

1977-1984

M.D.

Medicine

National Yang-Ming University, Taiwan

 

POSTDOCTORAL TRAINING

2001-2002

 

1999-2001

Calendar Binford Clinical Fellow, Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology (Supervisor: William D. Travis)

Resident, Anatomic Pathology, Washington University Medical Center/Barnes-Jewish Hospital

 

POSITIONS AND APPOINTMENTS

Health Care Facility Appointments

2017-present 2012-2017

2006-2012

2004-2006

Chair, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taiwan

Chief, Molecular Pathology Division, Taipei Veterans General Hospital, Taiwan

Chief, Surgical Pathology Division, Taipei Veterans General Hospital, Taiwan

Chief, General Pathology Division, Taipei Veterans General Hospital, Taiwan

 

Academic Appointments

2018-present

2018-present

2013-2017

Professor, Brain Research Center, Tsing-Hua University

Professor, Department of Biotechnology and Laboratory Science in Medicine, Yang-Ming University

Director, Institute of Clinical Medicine, Yang-Ming University

2011-present

Professor, Institute of Clinical Medicine, Yang-Ming University

SCIENTIFIC AND MEDICAL SOCIETIES

Leadership Positions

2014-2017

2009-2014

President, Taiwan Society of Pathology / Taiwan Division of International Academy of Pathology

Chair, Molecular Pathology Committee, Taiwan Society of Pathology

 

Membership

2019-present

2014-present

Chair, Membership Committee, Pulmonary Pathology Society (PPS)

Member, Pathology Committee, International Association for the Study of Lung Cancer (IASLC)

 

EXPERTISE

Medicine, Biochemistry, Molecular Biology, Thoracic Pathology, Molecular Mechanisms of Tumor Metastasis, Precision Medicine

 

PBLICATIONS

Selected Publications since 2014: (* Corresponding Author)

  1. Yeh YC, Ho HL, Wu YC, Pan CC, Wang YC, Chou TY. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma. Mod Pathol. 2019 Sep 16. [Epub ahead of print]
  2. Lin SC, Lin CH, Shih NC, Liu HL, Wang WC, Lin KY, Liu ZY, Tseng YJ, Chang HK, Lin YC, Yeh YC, Minato H, Fujii T, Wu YC, Chen MY,*Chou TY.* Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling. Oncogene (2019) [Epub ahead of print]
  3. Ho HL, Kao HL, Yeh YC, Chou TY. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies. Diagn Pathol. 2019 Jun 21;14(1):59
  4. Chang WC, Yeh YC, Ho HL, Hsieh SL, Chou TY. Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome. Am J Clin Pathol. 2019 Jul 5;152(2):207-216
  5. Yeh YC, Kao HL, Lee KL, Wu MH, Ho HL, Chou TY. Epstein-Barr Virus-Associated Pulmonary Carcinoma: Proposing an Alternative Term and Expanding the Histologic Spectrum of Lymphoepithelioma-like Carcinoma of the Lung. Am J Surg Pathol. 2019 Feb;43(2):211-219.
  6. Kao HL, Yeh YC, Lin CH, Hsu WF, Hsieh WY, Ho HL,* Chou TY.* Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods. Lung Cancer (2016) 101:40-47
  7. Hung JJ,* Yeh YC, Jeng WJ, Wu KJ, Huang BS, Wu YC,* Chou TY,* Hsu WH.* Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival. Journal of Clinical Oncology (2014) 32(22)2357-2364
  8. Chiu CH, Ho HL, Chiang CL, Lin SF, Ma HH, Chuang YT, Lin KY, Tsai CM, Chou TY.* Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR Mutation Testing Results Derived from PCR-Direct Sequencing and Real-Time PCR-Based Assays. Journal of Thoracic Oncology (2014) 9(1):91-96

 

BOOK CHAPTERS

1.     Chou TY,* Cooper WA, Kerr KM. PD-L1 22C3 PharmDx Assay. In: Tsao MS, Kerr KM, eds. IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, Editorial Rx Press, Aurora, Colorado 80011, USA, 2017; Chapter 5: 55-62